RPR Gencell reshuffles its cards

RPR Gencell reshuffles its cards

Rhone-Poulenc Rorer Inc. is using the flexibility of its RPR Gencell division to reshuffle its gene therapy bets, de-emphasizing ex vivo therapy and bringing in more of the latest in genomics and other drug discovery technologies.

The latest move

Read the full 438 word article

How to gain access

Continue reading with a
two-week free trial.